Inclusion Criteria:

- At least 18 years of age at the time of signing the informed consent form.

- Patient must have histologically or cytologically confirmed metastatic or locally advanced and recurrent NSCLC which is progressing.

- Patients eligible for second- or later-line therapy, who must have received an antiPD1/PD-L1 containing therapy and a platinum-doublet regimen for locally advanced or metastatic NSCLC either separately or in combination. Prior durvalumab is acceptable. The patient must have had disease progression on a prior line of antiPD1/PD-L1 therapy.

- ECOG/WHO performance status of 0 to 1, and a minimum life expectancy of 12 weeks.

- Patient must have at least 1 lesion that can be accurately measured. A previously irradiated lesion can be considered a target lesion if the lesion has clearly progressed.

- Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.


Exclusion Criteria:

- Patients whose tumour samples have targetable alterations in EGFR and/or ALK at initial diagnosis are excluded. In addition, patients whose tumour samples are known to have targetable alterations in ROS1, BRAF, MET or RET, are to be excluded.

- Active or prior documented autoimmune or inflammatory disorders.

- Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies).

- Female patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not willing to employ effective birth control.

- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients, or history of severe hypersensitivity reactions to other monoclonal antibodies.

- Patient has spinal cord compression or symptomatic brain metastases.

- Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Patients may receive treatment with bisphosphonates or receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitors for the treatment of bone metastases.

-history of active primary immunodeficiency

Locations

No attachments posted.

Purpose

Inclusion Criteria:

- At least 18 years of age at the time of signing the informed consent form.

- Patient must have histologically or cytologically confirmed metastatic or locally advanced and recurrent NSCLC which is progressing.

- Patients eligible for second- or later-line therapy, who must have received an antiPD1/PD-L1 containing therapy and a platinum-doublet regimen for locally advanced or metastatic NSCLC either separately or in combination. Prior durvalumab is acceptable. The patient must have had disease progression on a prior line of antiPD1/PD-L1 therapy.

- ECOG/WHO performance status of 0 to 1, and a minimum life expectancy of 12 weeks.

- Patient must have at least 1 lesion that can be accurately measured. A previously irradiated lesion can be considered a target lesion if the lesion has clearly progressed.

- Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.


Exclusion Criteria:

- Patients whose tumour samples have targetable alterations in EGFR and/or ALK at initial diagnosis are excluded. In addition, patients whose tumour samples are known to have targetable alterations in ROS1, BRAF, MET or RET, are to be excluded.

- Active or prior documented autoimmune or inflammatory disorders.

- Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies).

- Female patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not willing to employ effective birth control.

- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients, or history of severe hypersensitivity reactions to other monoclonal antibodies.

- Patient has spinal cord compression or symptomatic brain metastases.

- Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Patients may receive treatment with bisphosphonates or receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitors for the treatment of bone metastases.

-history of active primary immunodeficiency

Locations

Oversight

More Information